Julian Andreev, Ph.D. - Publications

Affiliations: 
New York University, New York, NY, United States 
Area:
tyrosine phosphorylation

16 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Bay AP, Faulkner D, Tiwari S, Castanaro C, Zheng X, Kunz A, Nittoli T, Han A, Olson W, Thurston G, Daly C, Andreev J. Abstract 2898: A biparatopic HER2xHER2 antibody drug conjugate with potent anti-tumor activity Cancer Research. 80: 2898-2898. DOI: 10.1158/1538-7445.Am2020-2898  0.368
2019 DaSilva JO, Yang K, Perez Bay AE, Andreev J, Ngoi P, Pyles E, Franklin MC, Dudgeon D, Rafique A, Dore A, Delfino FJ, Potocky T, Babb R, Chen G, MacDonald D, et al. A biparatopic antibody that modulates MET trafficking exhibits enhanced efficacy compared to parental antibodies in MET-driven tumor models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31848185 DOI: 10.1158/1078-0432.Ccr-19-2428  0.325
2019 Bay AP, Kalsy A, Tiwari S, Luan B, Kunz A, Chen Z, Zhang L, Potocky T, Nittoli T, Thurston G, Daly C, Andreev J. Abstract 233: Bispecific HER2 ADC: Making more potent HER2 ADC by improving target internalization Cancer Research. 79: 233-233. DOI: 10.1158/1538-7445.Am2019-233  0.375
2017 Kelly MP, Hickey C, Makonnen S, Coetzee S, Jalal S, Wang Y, Delfino F, Shan J, Potocky TB, Chatterjee I, Andreev J, Kunz A, D'Souza C, Giurleo JT, Nittoli T, et al. Preclinical activity of the novel anti-Prolactin Receptor (PRLR) antibody drug-conjugate REGN2878-DM1 in PRLR positive breast cancers. Molecular Cancer Therapeutics. PMID 28377489 DOI: 10.1158/1535-7163.Mct-16-0839  0.347
2017 Andreev J, Thambi N, Perez Bay AE, Delfino FJ, Martin JH, Kelly MP, Kirshner JR, Rafique A, Kunz A, Nittoli T, MacDonald D, Daly C, Olson W, Thurston G. Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs. Molecular Cancer Therapeutics. PMID 28108597 DOI: 10.1158/1535-7163.Mct-16-0658  0.398
2015 Kuhnert F, Chen G, Coetzee S, Thambi N, Hickey C, Shan J, Kovalenko P, Noguera-Troise I, Smith E, Fairhurst J, Andreev J, Kirshner JR, Papadopoulos N, Thurston G. Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer. Cancer Research. PMID 26377940 DOI: 10.1158/0008-5472.Can-14-3773  0.331
2015 Kelly MP, Coetzee S, Hickey C, Makonnen S, Delfino F, Andreev J, Kunz A, D'Souza C, Giurleo J, Nittoli T, Trail PA, Papadopoulos N, Thurston G, Kirshner JR. Abstract C126: PRLR ADC: A novel antibody drug-conjugate for the treatment of PRLR positive breast cancer Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-C126  0.364
2015 Andreev J, Thambi N, Delfino F, Martin J, Kelly MP, Kirshner JR, MacDonald D, Popadopoulos N, Olson W, Thurston G. Abstract A131: Rapid constitutive internalization and degradation of prolactin receptor (PRLR) is associated with potent cell killing by PRLR antibody drug conjugates (ADC) Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-A131  0.427
2001 Andreev J, Galisteo ML, Kranenburg O, Logan SK, Chiu ES, Okigaki M, Cary LA, Moolenaar WH, Schlessinger J. Src and Pyk2 mediate G-protein-coupled receptor activation of epidermal growth factor receptor (EGFR) but are not required for coupling to the mitogen-activated protein (MAP) kinase signaling cascade. The Journal of Biological Chemistry. 276: 20130-5. PMID 11274221 DOI: 10.1074/Jbc.M102307200  0.462
1999 Mandiyan V, Andreev J, Schlessinger J, Hubbard SR. Crystal structure of the ARF-GAP domain and ankyrin repeats of PYK2-associated protein beta. The Embo Journal. 18: 6890-8. PMID 10601011 DOI: 10.1093/Emboj/18.24.6890  0.477
1999 Andreev J, Simon JP, Sabatini DD, Kam J, Plowman G, Randazzo PA, Schlessinger J. Identification of a new Pyk2 target protein with Arf-GAP activity. Molecular and Cellular Biology. 19: 2338-50. PMID 10022920 DOI: 10.1128/Mcb.19.3.2338  0.514
1998 Isakoff SJ, Cardozo T, Andreev J, Li Z, Ferguson KM, Abagyan R, Lemmon MA, Aronheim A, Skolnik EY. Identification and analysis of PH domain-containing targets of phosphatidylinositol 3-kinase using a novel in vivo assay in yeast. The Embo Journal. 17: 5374-87. PMID 9736615 DOI: 10.1093/Emboj/17.18.5374  0.506
1995 Andreev J, Borovsky Z, Rosenshine I, Rottem S. Invasion of HeLa cells by Mycoplasma penetrans and the induction of tyrosine phosphorylation of a 145-kDa host cell protein. Fems Microbiology Letters. 132: 189-94. PMID 7590171 DOI: 10.1111/J.1574-6968.1995.Tb07832.X  0.375
1994 Andreev J, Dibrov PA, Klein D, Braun S. Chemotaxis, sporulation, and larvicide production in Bacillus sphaericus 2362. The influence of L-ethionine, and of aminophenylboronic acid. Febs Letters. 349: 416-9. PMID 8050606 DOI: 10.1016/0014-5793(94)00714-4  0.302
1994 Andreev J, Dibrov PA, Klein D, Braun S. Chemotaxis, sporulation, and larvicide production in Bacillus sphaericus 2362. The influence of L-ethionine, and of aminophenylboronic acid. Febs Letters. 347: 231-4. PMID 8034009 DOI: 10.1016/0014-5793(94)00538-9  0.302
1994 Andreev J, Dibrov PA, Braun S. Motility and chemotaxis in Bacillus sphaericus. Dependence upon stage of growth. Febs Letters. 347: 226-30. PMID 8034008 DOI: 10.1016/0014-5793(94)00537-0  0.312
Show low-probability matches.